However, patients with KMT2A-rearranged ALL occasionally show CD19 antigen loss after blinatumomab and blinatumomab may also be less effective than in non-KMT2A-rearranged ALL, due to lower CD19 expression. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.